Important:

This article is for information purposes only.

Please remember that financial investments may rise or fall and past performance does not guarantee future performance in respect of income or capital growth; you may not get back the amount you invested.

There is no obligation to purchase anything but, if you decide to do so, you are strongly advised to consult a professional adviser before making any investment decisions.

Sygnature Discovery to invest £3m in new instrumentation

Nottingham

The company is making the investment at its sites in Nottingham and Alderley Park to strengthen its oncology service offerings

A company which helps to develop new drugs has announced plans to invest more than £3 million in new instrumentation and equipment at two of its laboratories.

Contract research organisation Sygnature Discovery is making the multi-million pound investment at its sites at BioCity in Nottingham and Alderley Park to strengthen its high-throughput screening (HTS) and translational oncology service offerings.

The cash boost will allow the firm to enhance its integrated oncology capabilities and install an automated plate and tube storage system – with the capacity to hold over two million plated compounds and 135,000 in tubes – at its Nottingham base early next year.

Sygnature founder and CEO Dr Simon Hirst said: Despite the challenges brought about by the Covid-19 pandemic during 2020, Sygnature Discovery has continued to deliver top quality science to accelerate customers’ drug discovery programmes, combined with stellar growth in revenue and profitability. As a consequence, we have chosen to invest a further £3 million in early 2021 in new instrumentation and equipment to boost our HTS and translational oncology capabilities.

He said that this considerable funding injection will enable Sygnature to provide an even more comprehensive integrated service offering from hit identification to pre-clinical candidate selection. We have reached an exciting point in our company’s 16-year history, and 2021 will undoubtedly bring even more exciting developments for our business.

Sygnature Discovery is an independent integrated drug discovery and pre-clinical services company.

Since 2011, 33 compounds discovered by Sygnature for clients have entered pre-clinical development and, so far, 16 of these have progressed to clinical trials.

Earlier this year, the company won the national Medilink Outstanding Achievement Award while Dr Simon Hirst was a finalist in the UK EY Entrepreneur of The Year award.

Important:

This article is for information purposes only.

Please remember that financial investments may rise or fall and past performance does not guarantee future performance in respect of income or capital growth; you may not get back the amount you invested.

There is no obligation to purchase anything but, if you decide to do so, you are strongly advised to consult a professional adviser before making any investment decisions.